BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

The announcement could shake up the market for such injections, since the shortage designation allowed compounding pharmacies ...

A surge of alternatives to newly popular weight-loss drugs is facing its biggest test yet after the FDA warned companies ...

The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...

Arrowhead's plozasiran shows promising Phase 3 data for FCS, with potential blockbuster status, but faces competition. Learn ...

But regardless of what patients take them for, there is an outstanding concern: the muscle loss that often accompanies rapid ...

Muscle-sparing is particularly important in patients with heart failure as it is associated with higher mortality.